MedTrace Logo

Association Between Genetic Variant Scores and Warfarin Effect

NCT03894878 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-02-16

No results posted yet for this study

Summary

Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥ 4, bleeding event, ischemic stroke, death) in participants taking warfarin for atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and/or intracardiac thrombosis.

Conditions

Sponsors & Collaborators

  • Santa Clara Valley Medical Center

    collaborator OTHER

  • Cipherome, Inc.

    lead INDUSTRY

Principal Investigators

  • Clifford Wang, MD · Santa Clara Valley Medical Center

  • Dayani Nualles-Percy, MD · Santa Clara Valley Medical Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03894878 on ClinicalTrials.gov